CAR T-Cell therapy sends multiple myeloma into lasting remission – EurekAlert (press release)
FierceBiotech |
CAR T-Cell therapy sends multiple myeloma into lasting remission
EurekAlert (press release) “While it’s still early, these data are a strong sign that CAR T-cell therapy can send multiple myeloma into remission,” said ASCO Expert Michael S. Sabel, MD, FACS. “It’s rare to see such high response rates, especially for a hard-to-treat cancer … ASCO dark horse Nanjing Legend Biotech shines with promising CAR–T dataFierceBiotech Chinese cell therapy effective in small multiple myeloma trialReuters bluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter …Business Wire (press release) TheStreet.com –Endpoints News all 8 news articles » |
NPR |
CRISPR, Five Ways
NPR CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is the basis for a revolutionary genome-editing technology that allows researchers to make very precise modifications to DNA. The implications are enormous — not only … |
NPR |
Five Different Ways To Explain CRISPR : 13.7: Cosmos And Culture …
NPR A new video offers a valuable introduction to CRISPR — and illustrates how understanding can evolve from a relatively short description to a dialogue with more … |
EurekAlert (press release) |
CRISPR tech leads to new screening tool for Parkinson’s disease
EurekAlert (press release) They are using CRISPR Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology. The system is one of research’s fastest growing biomedical techniques that allows scientists to make specific changes in the DNA of plants … |
|
A first: All respond to gene therapy in a blood cancer study
ABC News Doctors are reporting unprecedented success from a new kind of cell and gene therapy for multiple myeloma, a blood cancer that’s on the rise. Although it’s early and the study is small, 35 people, every patient responded to treatment and all but two … |
|
A first: All respond to gene therapy in a blood cancer study
ABC News Doctors are reporting unprecedented success from a new kind of cell and gene therapy for multiple myeloma, a blood cancer that’s on the rise. Although it’s early and the study is small, 35 people, every patient responded to treatment and all but two … |
|
HalioDx : HalioDx highlights use of Immunosign® to define CAR T-cell therapy signature in tumor at ASCO 2017
GlobeNewswire (press release) For the first time, a tumor microenvironment immune gene signature associated with CAR T-cell treatment of non-Hodgkin lymphoma (NHL) patients has been described. Data analysis pointed to immune programs which may facilitate or modulate anti-tumor … |